Optimization of Autologous Muscle Stem Cell Survival in the Denervated Hemilarynx

Authors

  • Stacey L. Halum MD,

    Corresponding author
    1. From the Department of Otolaryngology–Head and Neck Surgery, Indiana University, 950 West Walnut Street, Indianapolis, Indiana, U.S.A.
    • Send correspondence to Stacey L. Halum, MD, Indiana University, Dept. of Otolaryngology–Head and Neck Surgery, 702 Barnhill Drive, Suite 860, Indianapolis, IN 46202, U.S.A.
    Search for more papers by this author
  • Kelly K. Hiatt MD, PhD,

    1. From the Department of Otolaryngology–Head and Neck Surgery, Indiana University, 950 West Walnut Street, Indianapolis, Indiana, U.S.A.
    Search for more papers by this author
  • Moumita Naidu BS,

    1. From the Department of Otolaryngology–Head and Neck Surgery, Indiana University, 950 West Walnut Street, Indianapolis, Indiana, U.S.A.
    Search for more papers by this author
  • Ahmed S. Sufyan BS,

    1. From the Department of Otolaryngology–Head and Neck Surgery, Indiana University, 950 West Walnut Street, Indianapolis, Indiana, U.S.A.
    Search for more papers by this author
  • D. Wade Clapp MD

    1. From the Department of Neonatology, Indiana University, 950 West Walnut Street, Indianapolis, Indiana, U.S.A.
    Search for more papers by this author

  • Editor's Note: This Manuscript was accepted for publication February 6, 2008.

Abstract

Objective: Current treatments for vocal fold paralysis are suboptimal in that they fail to restore dynamic function. Autologous muscle stem cell (MSC) therapy is a promising potential therapy for vocal fold paralysis in that it can attenuate denervation-induced muscle atrophy and provide a vehicle for delivery of neurotrophic factors, thereby potentially selectively guiding reinnervation. The goal of this project was to characterize optimal conditions for injected autologous MSC survival in the thyroarytenoid (TA) muscle following recurrent laryngeal nerve (RLN) injury by local administration of adjuvant factors.

Study Design: Animal experiment.

Methods: Unilateral RLN transection and sternocleidomastoid muscle (∼1 g) biopsies were performed in 20 male Wistar rats. One month later, 106 autologous MSCs labeled via retroviral-enhanced green fluorescent protein (EGFP) transduction were injected into the denervated hemilarynx of each animal with one of four adjuvant therapies: cardiotoxin [(CTX) 10−5 M], insulin-like growth factor-1 [(IGF- 1) 100 μg/mL], ciliary neurotrophic factor [(CNTF) 50 μg/mL], or saline. Animals were euthanized 1 month later and larynges harvested, sectioned, and analyzed for MSC survival.

Results: All specimens demonstrate extensive MSC survival, with fusion of the MSCs with the denervated myofibers. Based on mean fluorescent intensity of the laryngeal specimens, IGF-1 and CNTF had the greatest positive influence on MSC survival. Myofiber diameters demonstrated myofiber atrophy to be inversely related to MSC survival, with the least atrophy in the groups having the greatest MSC survival.

Conclusions: Autologous MSC therapy may be a future treatment for vocal fold paralysis. These findings support a model whereby MSCs genetically engineered to secrete CNTF and/or IGF-1 may not only promote neural regeneration, but also enhance MSC survival in an autocrine fashion.

Ancillary